It remains challenging to predict the clinical efficacy of novel immunotherapies from in vitro data and animal models, especially when evaluating vaccines against Plasmodium falciparum, the parasite which causes the most dangerous type of malaria.
Groups at the University of Oxford led by Simon Draper and Sumi Biswas are developing soluble protein and nanoparticle vaccines against the blood stage and mosquito stage of malaria respectively. To expedite the long timelines associated with GMP manufacture in preparation for clinical trials, we are applying a standard purification process for all the candidate vaccines. The process employs affinity chromatography, enabled by the addition of a 4 amino-acid ‘C-tag’ to the terminus of each vaccine. It can be rapidly adapted to new vaccine candidates, enabling efficient translation into clinical trials.
In this webinar we will cover the following main areas:
- Challenges associated with developing an effective vaccine against malaria, and current status of the field
- Nanoparticle and soluble protein vaccine candidates developed by the University of Oxford, focusing on the GMP manufacture and clinical testing of RH5.1
- Overview of C-tag technology for straightforward purification of proteins and particles
- Thermo Scientific™ CaptureSelect™ affinity chromatography technology and resin development for cGMP manufacturing of biomolecules